Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights
04. August 2022 16:05 ET
|
Lyell Immunopharma, Inc
Cash, cash equivalents and marketable securities of $787.0 million as of June 30, 2022 provides funding into 2025 and supports advancement of multiple product candidates through key clinical...
Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference
07. Juni 2022 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies...
Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights
10. Mai 2022 16:05 ET
|
Lyell Immunopharma, Inc
Cash, cash equivalents and marketable securities of $838 million as of March 31, 2022 supports advancing a robust cell therapy pipelineResearch highlighting novel reprogramming technologies designed...
Lyell Immunopharma to Participate in BofA Securities Healthcare Conference
04. Mai 2022 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid...
Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting
02. Mai 2022 16:30 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid...
Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
29. März 2022 16:05 ET
|
Lyell Immunopharma, Inc
Cash, cash equivalents and marketable securities of $898 million as of December 31, 2021 supports advancing multi-modality cell therapy pipelineClinical development commencing for two programs that...
Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting
08. März 2022 16:45 ET
|
Lyell Immunopharma, Inc
LYL797 is an investigational ROR1 CAR T-cell therapy incorporating novel reprogramming technologies for solid tumors SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Lyell...
Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer
31. Januar 2022 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...
Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK
24. Januar 2022 08:00 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...
Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference
04. Januar 2022 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...